Gerd R Burmester on Muck Rack

Gerd R Burmester

Berlin
As seen in: Annals of the Rheumatic Diseases, BMJ Open, Arthritis Research & Therapy, The Lancet, Healio, Healio Rheumatology, The Journal of Rheumatology
Professor of Medicine, Director, Department of Rheumatology and Clinical Immunology, Charité - University Medicine Berlin. EULAR International Liaison Officer.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Gerd R

Contact Gerd R, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)

|
By Gerd R Burmester, John R.P. Tesser, Anna Shmagel, Yanxi Liu
| The Journal of Rheumatology Verified
Key Indexing Terms: arthritis clinical trials Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects joints, causes progressive bone and cartilage damage, and impairs quality of life if treated inadequately.1,2 The primary goal of RA therapy is to achieve sustained remission or low disease activity (LDA).
Open in Who Shared Issue with article?

Upadacitinib’s risk-benefit profile in rheumatoid arthritis ‘favorable’ through 5 years

|
By Justin Cooper Verified, Shenaz Bagha Verified, Gerd R Burmester
| Healio Verified
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: The initial clinical outcomes of upadacitinib for RA “improved or were maintained” through 5 years. Major adverse cardiovascular events and venous thromboembolisms were infrequent.
Open in Who Shared Issue with article?

Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years

|
By Gerd R Burmester, Jacques-Eric Gottenberg, Roberto Caporali, Kevin L. Winthrop
| Annals of the Rheumatic Diseases Verified
Antirheumatic Agents Arthritis, Rheumatoid Therapeutics Data availability statement Data are available upon reasonable request. Anonymised individual patient data will be shared upon request for research purposes, dependent upon the nature of the request, the merit of the proposed research and the availability of the data and their intended use. The full data sharing policy for Gilead Sciences, Inc., can be found at https://www.gilead.com/about/ethics-and-code-of-conduct/policies.
Open in Who Shared View Duplicates (2) Issue with article?
See all 62 licensed articles (65 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified